Atlas Trials

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Clinical trial NCT05907057 · RECRUITING

Trial details

NCT number
NCT05907057
Sponsor
Servier Affaires Médicales
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Acute Myeloid Leukemia (AML)
Start date
2023-06-14
Primary completion
2027-10-15
Enrollment
245

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.